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Abstract
Background: Growth hormone deficiency (GHD) is associated with non-alcoholic fatty liver disease (NAFLD). A recent
animal study showed that hepatocyte-specific receptor activator of nuclear factor-kappa B (RANK) knockout mice had
significantly lower liver fat content compared with control mice concomitant with a decrease in production of
inflammatory cytokines such as tumor necrosis factor-α (TNF-α) from hepatocytes and kupffer cells. The role of
anti-RANK ligand (RANKL) antibody for osteoporosis on hepatitis in patients with aGHD is still unknown.
Case presentation: A forty-seven-year-old female patient was referred to our hospital to investigate chronic
hepatitis caused by unknown etiology. She had past history of craniopharyngioma treated with craniotomy and
post-surgical radiotherapy. She was for the first time diagnosed as panhypopituitarism including growth hormone
deficiency and osteoporosis by endocrine examinations and bone mineral densitometry, respectively. In addition,
non-alcoholic steatohepatitis (NASH) was histologically confirmed by liver biopsy in this time. Sixty mg anti-RANKL
antibody, which was subcutaneously injected to treat the osteoporosis every six months after replacement of
5 mg hydrocortisone and 30 μg oral desmopressin, rapidly decreased the levels of her liver enzymes (ALT and
γGTP were 133 to 72 U/L and 284 to 99 U/L at 16 months after the beginning of the treatment, respectively).
Additional amelioration of liver dysfunction was not observed after growth hormone replacement.
Conclusions: The clinical course of the present case suggested that RANKL-RANK signaling may be a key
pathological mechanism in establishment or development of NAFLD or NASH in patients with panhypopituitarism
including GHD.
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Background
Non-alcoholic fatty liver disease (NAFLD) defines liver
abnormalities ranging from simple steatosis to non-
alcoholic steatohepatitis (NASH) with or without cir-
rhosis development. Prevalence of NAFLD is massively
increasing because that is related to obesity [1]. Re-
cently, several clinical studies have shown that growth
hormone deficiency (GHD) is complicated with NAFLD
[2, 3] and that growth hormone (GH) replacement ther-
apy improves liver dysfunction [4–6] and histological
findings of NAFLD [4, 6], suggesting that GHD is con-
sidered as one of the pathological causes for NAFLD.
However, detailed mechanisms of establishment of
NAFLD in patients with GHD are still unknown.
Receptor activator of nuclear factor-kappa B ligand
(RANKL) is an osteoclast differentiating factor which
binds to receptor activator of nuclear factor-kappa B
(RANK) on the surface of osteoclasts and enhances
osteoclast differentiation, function and bone resorption
[7]. An anti-RANKL antibody, denosumab, is clinically
used as an anti-osteoporotic agent which increases
bone mineral density (BMD) by inhibiting bone resorp-
tion [8, 9]. We report the first case of adult-GHD
(aGHD) that administration of anti-RANKL antibody
for the treatment of osteoporosis was associated with
amelioration of hepatitis.
Case presentation
A 47-year-old debile female patient was referred to
our hospital to examine hepatitis caused by unknown
etiology. At 11 years of age, she was diagnosed as cra-
niopharyngioma and treated with craniotomy and
post-surgical radiotherapy. Sex hormone replacement
was performed for hypogonadotropic hypogonadism
from 15 to 44 years old. Elevated liver enzymes were
observed about past 20 years.
She was an underweight woman (body height, 149.3 cm;
body weight, 36.5 kg; BMI 16.4 kg/m2) who had no
alcohol consumption. Laboratory findings showed
elevated liver enzymes (AST, ALT and γGTP were 131
U/L, 106 U/L and 238 U/L, respectively) concomitant
with an extremely low concentration of insulin-like
growth factor-1 (IGF-1) (12 ng/mL) (Table 1). Abdom-
inal ultrasonography showed fatty liver. Hepatitis B
surface antigen, anti-hepatitis C virus antibody, anti-
nuclear antibody and anti-mitochondrial M2 antibody
were undetectable. Histological findings of the liver bi-
opsy were compatible with NASH (Fig. 1a–d).
aGHD was diagnosed by loading test with 100 μg GH-
releasing peptide-2 (GHRP-2) [basal level: 0.1 ng/mL,
peak level: 0.4 ng/mL at 15 min]. She was diagnosed as
ACTH, TSH, LH and FSH insufficiency as well as cen-
tral diabetes insipidus by additional loading tests.
Osteoporosis was diagnosed by BMD [T-score of the
lumbar spine and the femoral neck were −2.0 SD and
−2.5 SD, respectively].
The therapeutic course was shown in Fig. 2. The levels
of liver enzymes did not change for three months after
the replacement of hydrocortisone (5 mg/day) and oral
desmopressin (30 μg/day). When 60 mg anti-RANKL
antibody was subcutaneously injected to treat the osteo-
porosis every six months, the levels of her liver enzymes
were rapidly decreased after the first and second admin-
istration (levels of ALT and γGTP at nine months later
were 60 U/L and 117 U/L, respectively). Then, GH
Table 1 Laboratory tests
Level measured Reference range
《Biochemical Profiles》
AST 131 U/L (10–38)
ALT 106 U/L (5–40)
γGTP 238 U/L (0–75)
ALP 439 U/L (21–80)
BUN 7.4 mg/dL (8.0–21.0)
Cr 0.53 mg/dL (0.44–0.83)
Na 145 mEq/L (137–146)
K 3.5 mEq/L (3.5–4.9)
Cl 111 mEq/L (98–109)
LDL-C 98 mg/dL (70–139)
HDL-C 38 mg/dL (40–80)
TG 106 mg/dL (50–140)
HbA1c 5.7% (4.7–6.2)
FPG 78 mg/dL (60–109)
《Endocrine Profiles》
GH 0.1 ng/mL (<3.0)
IGF-1 12 ng/mL (83–221)
PRL 13.3 ng/mL (3.2–26.2)
LH <0.2 mIU/mL (1.13–88.33)
FSH <0.1 mIU/mL (3.01–16.60)
E2 <7 pg/mL (7–509)
TSH 4.76 μU/mL (0.50–3.00)
FT4 0.6 ng/dL (0.8–1.5)
FT3 2.4 pg/mL (2.1–3.8)
ACTH 17.4 pg/mL (7.2–63.3)
cortisol 2 μg/dL (2–18)
u-cortisol undetectable (11.2–80.3)
ADH <0.8 pg/mL (<4.2)
s-Osm 289 mOsm/L (270–295)
u-Osm 250 L mOsm/L (50–1300)
GHRP-2 loading test
Time (min) 0 15 30 45 60
GH (ng/mL) 0.1 0.4 0.4 0.3 0.2
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replacement therapy (0.033 mg/kg/week after 0.017 mg/
kg/week for two month) and levothyroxine (25 μg/day)
were initiated, however, the levels of liver enzymes were
increased and were not changed despite improvement of
IGF-1 concentrations (ALT and γGTP were 114 U/L and
157 U/L at around 12 months after the beginning of the
treatment, respectively). However, the levels of liver en-
zymes were decreased again after third administration of
anti-RANKL antibody (ALT and γGTP were 72 U/L and
99 U/L at 16 months after the beginning of the treat-
ment, respectively).
Discussion
NASH is characterized by inflammation and fibrosis
in addition to fat deposition within hepatocytes.
Many pro-inflammatory cytokines including tumor
necrosis factor-α (TNF-α) are involved in the pro-
gression of NASH [10–12]. A recent study showed
that hepatocyte-specific RANK knockout mice had
significantly lower liver fat content compared with
control mice concomitant with a decrease in produc-
tion of inflammatory cytokines such as TNF-α from
hepatocytes and kupffer cells [13], indicating that
RANKL-RANK signaling pathway potentially is asso-
ciated with hepatitis. In our case, the amelioration of
liver enzymes was associated with the administration
of anti-RANKL antibody, suggesting that RANKL-
RANK signaling pathway may be one of the potential
pathogenesis for the development of NAFLD or
NASH under the condition of panhypopituitarism in-
cluding GH deficiency.
Unlike previous cases [4–6], GH replacement ther-
apy was not clearly associated with liver dysfunction
in this case. Sufficient dose of GH was given to her
because her IGF-1 levels were within normal range
for her age. Matsumoto et al. reported that improve-
ment of liver dysfunction after GH replacement in
GHD patients was observed at least within three
months [5], indicating that short duration of the GH
replacement was not the reason for prolonged liver
dysfunction in this case. In contrast to previous cases,
GH was replaced under the administration of anti-
RANKL antibody in this case. The finding that GH
replacement after administration of anti-RANKL anti-
body was not effective suggested that mechanism of
amelioration of hepatitis by GH replacement therapy
may be identical with inhibition of RANK signaling
for production of inflammatory cytokines in hepato-
cytes. This observation indicated that RANKL-RANK
signaling may play a crucial role in progression of
NAFLD or NASH in patients with panhypopituitarism
including GH deficiency.
Fig. 1 Liver biopsy samples. Hematoxylin and eosin (H&E) staining showed steatosis (50%), infiltrations of inflammatory cells and hepatocyte
ballooning (Fig. 1a and b: ×100 and ×400, respectively). Azan-mallory staining showed fibrosis of portal region (Fig. 1c: ×100), and silver staining
showed pericellular fibrosis (Fig. 1d: ×400). These findings were compatible to the diagnosis of NASH. These findings were compatible with NASH
(grade 2 and stage 2)
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Conclusions
Present case showed that administration of anti-RANKL
antibody for the treatment of osteoporosis was associ-
ated with amelioration of hepatitis in a women patient
with aGHD concomitant with NASH. The clinical
course of the present case suggested that RANKL-
RANK signaling may be a key pathological mechanism
in development of NASH in patients with panhypopitui-
tarism including GH deficiency. Agents to inhibit
RANK-RANKL signaling in hepatocytes might be bene-
ficial for treatment of NASH in these populations.
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Fig. 2 Changes in the liver enzymes, body weight and IGF-1 after
the initiation of hormone replacement and anti-RANKL antibody.
After the replacement of hydrocortisone 5 mg/day and oral
desmopressin 30 μg/day, the liver enzymes were unchanged.
Three months later anti-RANKL antibody 60 mg was administered, and
plasma levels of ALT and γGTP were decreased from 133 to 62 U/L and
from 284 to 171 U/L, respectively. Reduction of liver enzymes was also
confirmed after second and third administration of anti-RANKL
antibody. GH and levothyroxin replacement were initiated between
the second and the third administration of anti-RANKL antibody,
and IGF-1 level was increased to normal range. However, the liver
enzymes were not decreased by replacement with GH and levothyroxin.
She gained 6.1 kg of weight during the treatment period
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